You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

XGEVA

Showing 1 - 25 of 62
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

This is a Phase Study Conducted in Healthy Volunteers, Osteoporosis Trial (Denosumab)

Not yet recruiting
  • This is a Phase Study Conducted in Healthy Volunteers
  • Osteoporosis
  • Denosumab
  • (no location specified)
May 17, 2023

Healthy Trial in Haikou (HS-20090, Xgeva®)

Not yet recruiting
  • Healthy
  • Haikou, Hainan, China
    Haikou People's Hospital
Mar 8, 2023

Healthy Volunteers Trial in Hefei (Post-change CMAB807X, Pre-change CMAB807X, Xgeva®)

Not yet recruiting
  • Healthy Volunteers
  • Post-change CMAB807X
  • +2 more
  • Hefei, Anhui, China
    The Second Hospital of Anhui Medical University
Apr 10, 2023

Giant Cell Tumor of Bone Trial (XGEVA®)

Not yet recruiting
  • Giant Cell Tumor of Bone
  • (no location specified)
Mar 3, 2022

Langerhans Cell Histiocytosis Trial in Athens (Denosumab 70 MG/ML [Xgeva])

Completed
  • Langerhans Cell Histiocytosis
  • Denosumab 70 MG/ML [Xgeva]
  • Athens, Attiki, Greece
    251 Hellenic AirForce & VA General Hospital, Dpt of Endocrinolog
Oct 1, 2022

Primary Hyperparathyroidism, Osteoporosis Trial in Ljubljana (Denosumab 60 MG/ML Prefilled Syringe [Prolia], Zoledronic Acid)

Enrolling by invitation
  • Primary Hyperparathyroidism
  • Osteoporosis
  • Denosumab 60 MG/ML Prefilled Syringe [Prolia]
  • Zoledronic Acid
  • Ljubljana, Slovenia
    Endocrinology Department
Nov 2, 2022

Fibrous Dysplasia, McCune Albright Syndrome Trial in Leiden (Denosumab 120 Mg/1.7 Ml Inj, Placebo)

Recruiting
  • Fibrous Dysplasia
  • McCune Albright Syndrome
  • Denosumab 120 Mg/1.7 Ml Inj
  • Placebo
  • Leiden, Netherlands
    Leiden University Medical Center
Jul 20, 2023

Primary Hyperparathyroidism Trial in New York (Denosumab, Placebo)

Terminated
Has Results
  • Primary Hyperparathyroidism
  • New York, New York
    Columbia University Medical Center
Oct 6, 2022

Bone Metastases Trial in Beijing (MW032, Xgeva)

Active, not recruiting
  • Bone Metastases
  • Beijing, Beijing, China
    Fifth Medical Center of PLA General Hospital
Aug 31, 2021

Adult Idiopathic Generalized Osteoporosis Trial in Omaha, New York (Denosumab)

Completed
Has Results
  • Adult Idiopathic Generalized Osteoporosis
  • Omaha, Nebraska
  • +1 more
Nov 15, 2022

Osteonecrosis of Jaw and Infection Among Nordic Cancer Patients

Completed
  • Osteonecrosis of the Jaw
  • Infection Leading to Hospitalization
    • (no location specified)
    Sep 1, 2021

    Giant Cell Tumor of Bone Trial in Beijing (Narlumosbart, Denosumab)

    Not yet recruiting
    • Giant Cell Tumor of Bone
    • Beijing, Beijing, China
      Beijing Ji Shui Tan Hospital
    Apr 16, 2023

    Bone Metastases From Solid Tumors Trial in Guangzhou (LY01011, Xgeva®)

    Recruiting
    • Bone Metastases From Solid Tumors
    • Guangzhou, China
      The First Affiliated Hospital of Guangdong Pharmaceutical Univer
    Jun 2, 2021

    Melanoma Stage Iii, Melanoma Stage Iv, Melanoma Trial in Chapel Hill (Denosumab, Pembrolizumab, Nivolumab)

    Active, not recruiting
    • Melanoma Stage Iii
    • +4 more
    • Chapel Hill, North Carolina
      UNC Lineberger Comprehensive Cancer Center
    Jul 20, 2022

    Bone Tumor Trial in Zibo (MW032, Xgeva®)

    Completed
    • Bone Tumor
    • Zibo, Shandong, China
      PKUCare Luzhong Hospital
    Mar 12, 2021

    Breast Cancer Trial in Stony Brook (Denosumab)

    Completed
    • Breast Cancer
    • Stony Brook, New York
      Stony Brook University Cancer Center
    Jan 19, 2022

    Urothelial Carcinoma, Kidney Cancer, Ureter Cancer Trial in Toronto (drug, other, dietary supplement)

    Completed
    • Urothelial Carcinoma
    • +3 more
    • Toronto, Ontario, Canada
      Princess Margaret Cancer Centre
    Nov 22, 2021

    Ovarian Carcinoma Trial in Israel, United States (Denosumab, Salpingo-Oophorectomy)

    Terminated
    Has Results
    • Ovarian Carcinoma
    • Denosumab
    • Salpingo-Oophorectomy
    • Boston, Massachusetts
    • +5 more
    May 23, 2022

    Metastatic Breast Cancer, Metastatic Prostate Cancer, Bone Metastases Trial in Austria, Germany, Switzerland (Denosumab (reduced

    Recruiting
    • Metastatic Breast Cancer
    • +2 more
    • Denosumab (reduced dosing)
    • Denosumab (standard dosing)
    • Feldkirch, Austria
    • +49 more
    Jan 30, 2023

    Critical Illness, Osteoporosis Trial in Australia (Denosumab 60 MG/ML, Zoledronic Acid 5Mg/Bag 100Ml Inj, Sodium Chloride 0.9%

    Recruiting
    • Critical Illness
    • Osteoporosis
    • Denosumab 60 MG/ML
    • +3 more
    • Sydney, New South Wales, Australia
    • +11 more
    Sep 26, 2022

    Bone Metastases Trial in Beijing, Guangzhou (QL1206, Xgeva)

    Unknown status
    • Bone Metastases
    • Beijing, Beijing, China
    • +1 more
    Sep 19, 2020

    Breast Tumor Female, Stage I Breast Cancer, Stage II Breast Cancer Trial in L'Hospitalet De Llobregat (Denosumab 120 MG/1.7 ML

    Active, not recruiting
    • Breast Neoplasm Female
    • +4 more
    • Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
    • L'Hospitalet De Llobregat, Barcelona, Spain
      Institut Català d'Oncologia - L'Hospitalet
    Nov 2, 2021

    Primary Hyperparathyroidism, Parathyroid Adenoma, Parathyroid Hyperplasia Trial in Aalborg (Cinacalcet 30 mg Tablet, Denosumab

    Completed
    Has Results
    • Primary Hyperparathyroidism
    • +2 more
    • Cinacalcet 30 mg Tablet
    • +3 more
    • Aalborg, Denmark
      Aalborg University Hospital
    May 1, 2021

    Multiple Myeloma Trial in Austria, Germany, Israel (Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA], Placebo 1.7 ml

    Active, not recruiting
    • Multiple Myeloma
    • Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
    • Placebo 1.7 ml Subcutaneous Solution
    • Graz, Austria
    • +9 more
    Aug 24, 2022

    Renal Cell Carcinoma, Clear Cell, Metastatic Kidney Cancer Trial in Australia (Pembrolizumab plus denosumab)

    Recruiting
    • Renal Cell Carcinoma, Clear Cell
    • Metastatic Kidney Cancer
    • Pembrolizumab plus denosumab
    • Albury, New South Wales, Australia
    • +15 more
    Feb 14, 2022